参考文献
[1]Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia[J]. Nat Genet, 2003, 34(2): 154-156. DOI: 10.1038/ng1161.
[2]Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9[J]. N Engl J Med, 2017, 376(1): 41-51. DOI: 10.1056/NEJMoa1609243.
[3]Han Y, Chen J, Chopra VK, et al. ODYSSEY EAST: Alirocumab efficacy and safety vs ezetiibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand[J]. J Clin Lipidol, 2020, 14(1): 98-108e108. DOI: 10.1016/j.jacl.2019.10.015.
[4] 韩雅玲 , 马颖艳 , 苏国海 , 等 . 阿利西尤单抗与依折麦布治疗高胆固醇血症合并心血管高危患者的疗效及安全性比较：ODYSSEY EAST 研究中国地区亚组分析 [J]. 中华心血管病杂志 , 2022, 48(7): 593-599.
[5]Huo Y, et al. Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial. Lancet Reg Health West Pac. 2023 Sep 28; 41:100907.
[6]Raal FJ,et al.N Engl J Med.2020;382(16）:1520-1530.
[7]Wright RS,et al.J Am Coll Cardiol.2021;77(9）:1182-1193.
首发：丁香园心血管时间
投稿：tangshixuan@dxy.cn
2024 内分泌领域年终盘点盛大来袭！
扫描下方二维码或点击文末「阅读原文」
即可预约直播，参与热词预测，赢取丁当～
⬇️ ⬇️ ⬇️
